NaviFUS (6872) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 浩宇生醫

NaviFUS (6872) reported revenue of NT$564,000 for Oct 2026, -19.0% year on year and -30.8% from the previous month. Revenue for Jan–Oct 2026 was NT$24.5 million (+167.9% year on year).

In Oct 2026, it ranked No. 149 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$8.1 million24/10Nov 2024 NT$450,000Dec 2024 NT$1.2 millionJan 2025 NT$350,000Feb 2025 NT$368,00025/02Mar 2025 NT$396,000Apr 2025 NT$399,000May 2025 NT$1.7 millionJun 2025 NT$1.5 million25/06Jul 2025 NT$602,000Aug 2025 NT$2.5 millionSep 2025 NT$665,000Oct 2025 NT$696,00025/10Nov 2025 NT$643,000Dec 2025 NT$683,000Jan 2026 NT$658,000Feb 2026 NT$665,00026/02Mar 2026 NT$16.9 millionApr 2026 NT$1.3 millionMay 2026 NT$821,000Jun 2026 NT$1.1 million26/06Jul 2026 NT$795,000Aug 2026 NT$852,000Sep 2026 NT$815,000Oct 2026 NT$564,00026/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$564,000-19.0%-30.8%
Sep 2026NT$815,000+22.6%-4.3%
Aug 2026NT$852,000-65.3%+7.2%
Jul 2026NT$795,000+32.1%-30.4%
Jun 2026NT$1.1 million-24.9%+39.1%
May 2026NT$821,000-51.8%-36.9%
Apr 2026NT$1.3 million+226.3%-92.3%
Mar 2026NT$16.9 million+4,172.0%+2,443.9%
Feb 2026NT$665,000+80.7%+1.1%
Jan 2026NT$658,000+88.0%-3.7%
Dec 2025NT$683,000-44.3%+6.2%
Nov 2025NT$643,000+42.9%-7.6%
Oct 2025NT$696,000-91.5%+4.7%
Sep 2025NT$665,000-84.8%-72.9%
Aug 2025NT$2.5 million+2,571.7%+308.3%
Jul 2025NT$602,000-92.6%-60.4%
Jun 2025NT$1.5 million-70.5%-10.6%
May 2025NT$1.7 million—+326.6%
Apr 2025NT$399,000—+0.8%
Mar 2025NT$396,000—+7.6%
Feb 2025NT$368,000—+5.1%
Jan 2025NT$350,000—-71.5%
Dec 2024NT$1.2 million+70.4%+172.7%
Nov 2024NT$450,000—-94.5%
Oct 2024NT$8.1 million—+86.6%

Jan–Oct 2026 cumulative: NT$24.5 million (+167.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: NaviFUS vs PEC / NaviFUS vs Lotus Pharm / NaviFUS vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

主係銷售醫療器材之收入增加所致

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16